Rare Daily Staff
Moderna and OpenAI announced an ongoing collaboration, which will integrate generative AI throughout the company to advance its mRNA therapeutics portfolio.
The organizations began their collaboration in early 2023 with the launch of Moderna’s own instance of ChatGPT, called mChat, which was internally built on top of OpenAI’s API. With more than 80 percent internal adoption since its debut, this initial success accelerated an AI culture that led to the deployment of ChatGPT Enterprise and its enhanced capabilities such as Advanced Analytics, Image Generation and GPTs. These GPTs are now embedded across Moderna’s business functions—from legal, to research, to manufacturing, to commercial—and are purpose-built as assistants that work beside Moderna’s employees, augmenting their roles through personalized support.
In the few months since adopting ChatGPT Enterprise, Moderna has deployed more than 750 GPTs across the company that help drive automation and productivity. This includes the Company’s Dose ID GPT, which uses ChatGPT Enterprise’s Advanced Data Analytics feature to further evaluate the optimal vaccine dose selected by the clinical study team.
By applying standard dose selection criteria and principles, Dose ID provides a rationale, references its sources, and generates informative charts illustrating the key findings. This allows for a detailed review, led by humans and augmented with AI input, while prioritizing safety and optimizing the vaccine dose profile prior to further development in late-stage clinical trials.
“Just as the introduction of the personal computer in the 1980’s changed the way we work and live, AI is on a path to completely transform our everyday lives—and OpenAI is helping to lead the way,” said Stéphane Bancel, CEO of Moderna. “Both our companies have shared values and are research-driven organizations pushing the boundaries of technology to drive transformation.”
Photo: Stéphane Bancel, CEO of Moderna
Stay Connected
Sign up for updates straight to your inbox.